1. Home
  2. KRRO vs KROS Comparison

KRRO vs KROS Comparison

Compare KRRO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$12.67

Market Cap

196.4M

Sector

Health Care

ML Signal

SELL

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

SELL

Current Price

$10.00

Market Cap

222.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KRRO
KROS
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.4M
222.7M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
KRRO
KROS
Price
$12.67
$10.00
Analyst Decision
Strong Buy
Buy
Analyst Count
11
7
Target Price
★ $21.50
$19.83
AVG Volume (30 Days)
★ 212.2K
170.6K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 146.00
EPS
N/A
★ N/A
Revenue
$6,392,000.00
★ $243,864,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 181.46
N/A
52 Week Low
$5.20
$8.98
52 Week High
$17.35
$22.55

Technical Indicators

Market Signals
Indicator
KRRO
KROS
Relative Strength Index (RSI) 48.28 43.48
Support Level $11.81 N/A
Resistance Level $14.47 $11.86
Average True Range (ATR) 1.45 0.75
MACD -0.22 -0.04
Stochastic Oscillator 24.60 36.90

Price Performance

Historical Comparison
KRRO
KROS

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: